Clinical Trial Update: Mutant KRAS -Targeted Long Peptide Vaccine for Patients at High Risk of Developing Pancreatic Cancer [Phase 1]

View source ↗

Summary

A Phase 1 trial is evaluating a mutant KRAS-targeted long peptide vaccine for people at high risk of developing pancreatic cancer, and the study is currently re…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Pancreatic Cancer

Drugs mentioned

• Mutant KRAS-targeted Long Peptide Vaccine

Snippet

Sponsor: Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins | Conditions: High Risk Cancer, Pancreatic Cancer | Phase 1 | Status: RECRUITING